FDA enforcement actions
Included forty-nine regulatory letters and 16 seizures during the first six months of 1990, Office of Compliance Deputy Director Sammie Young reported Sept. 18 in Bethesda, Md. Fourteen of the regulatory letters and eight of the seizures involved violations of Good Manufacturing Practices (GMPs). In all of 1989, 115 regulatory letters (including 48 concerning GMPs) were sent compared to 109 reg letters (35 for GMP violations) in 1988; and 106 (64 GMP) in 1987. There were 30 seizures (including 9 GMP violations) in 1989; 50 (9 GMP) in 1988; 50 (15 GMP) in 1987 and 83 (29 GMP) in 1986.
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.